Healthcare >> CEO Interviews >> October 17, 2003
JAMES NOBLE is Chief Executive Officer of Avidex Limited. Mr. Noble has
13 years' experience in the biotech industry, the first six as Finance
Director of British Biotech. He then spent four years as a part-time
Director at Oxagen Limited and non-executive Director at a range of
Biotech companies. These include three listed companies, Powderject
Pharmaceuticals (1997-2000), Oxford GlycoSciences (1997-2001) and
Advanced Medical Solutions (1997-2000, Chairman). He also has served on
a number of Boards of private companies and is currently a Director of
Oxfordshire Biotechnet Limited and Bionex Investments Plc. Prior to his
involvement in biotechnology, Mr. Noble spent seven years at Kleinwort
Benson, becoming a Director in 1990. There, he was responsible for a
wide range of clients across a number of sectors and was involved in a
large number of transactions, from privatizations to hostile takeovers
and fundraisings. Mr. Noble previously qualified as a Chartered
Accountant with Price Waterhouse in 1983 after graduating from Oxford in
1980. Profile
picture of the things you are doing today.
Mr. Noble: Avidex is almost exactly three years old. We are a spinout
from
